Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. QSI
QSI logo

QSI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.973
Open
0.950
VWAP
0.92
Vol
13.19M
Mkt Cap
197.42M
Low
0.880
Amount
12.14M
EV/EBITDA(TTM)
--
Total Shares
217.76M
EV
70.08M
EV/OCF(TTM)
--
P/S(TTM)
91.83
Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.
Show More

Events Timeline

(ET)
2026-05-07
16:50:00
Proteus Reports Q1 Revenue of $258K, Below Consensus
select
2026-04-28 (ET)
2026-04-28
08:40:00
Quantum-Si Achieves Sequencing on Integrated Proteus Instruments
select
2026-04-14 (ET)
2026-04-14
08:40:00
Quantum-Si Releases New Study on Human Cohesin Function in Yeast
select
2026-04-08 (ET)
2026-04-08
09:20:00
Quantum-Si Completes Sequencing on Proteus Prototype System
select
2026-03-04 (ET)
2026-03-04
15:50:00
IonQ Q4 Exceeds Expectations with $61.9 Million Revenue
select
2026-03-03 (ET)
2026-03-03
16:20:00
Company Reports Q4 Revenue of $451K, Below Expectations
select

News

seekingalpha
9.5
05-08seekingalpha
Quantum-Si Q1 2026 Earnings Call Insights
  • Revenue and Profit Overview: In Q1 2026, Quantum-Si reported revenue of $258,000 and gross profit of $74,000, resulting in a gross margin of 29%, indicating some progress in consumable sales despite overall revenue falling short of expectations.
  • Proteus Platform Progress: Management highlighted the technological advantages of the Proteus platform, noting its superior proteome coverage and signal quality compared to Platinum, with plans to achieve detection of 18 amino acids by the end of 2026, marking a significant milestone in product development.
  • 2026 Outlook: The company reiterated its targets for 2026, projecting total revenue of approximately $1 million, adjusted operating expenses of no more than $98 million, and total cash usage of less than $93 million, reflecting a focus on long-term platform adoption.
  • Liquidity and Financial Position: As of March 31, 2026, Quantum-Si had $190.4 million in cash and cash equivalents, expected to support operations into Q2 2028, indicating strong financial management and runway for future growth.
Newsfilter
1.0
05-01Newsfilter
Quantum-Si to Participate in H.C. Wainwright BioConnect Investor Conference
  • Investor Conference Participation: Quantum-Si will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, showcasing its innovative protein analysis technology, which is expected to attract potential investors and enhance the company's market visibility.
  • Executive Meeting Schedule: CEO Jeff Hawkins and CFO Jeff Keyes will hold one-on-one meetings throughout the conference, aiming to engage deeply with investors to bolster confidence and drive future funding opportunities.
  • Webcast Availability: The event will feature live and archived webcasts, allowing investors who cannot attend in person to access information, thereby expanding Quantum-Si's investor base and enhancing transparency.
  • Platform Technology Advantage: Quantum-Si's platform simplifies traditional multi-step workflows through single-molecule protein analysis, enabling researchers to obtain real-time insights into dynamic functional proteins, which accelerates proteomic discoveries and holds significant market application potential.
Newsfilter
3.5
04-28Newsfilter
Quantum-Si Achieves Milestone in Protein Sequencing with Proteus Instruments
  • Technical Milestone: Quantum-Si successfully demonstrated protein sequencing on integrated Proteus™ instruments using the KinetIQ™ Array, which detects 17 amino acids, showcasing rapid technological advancement since December 2025, thereby enhancing the company's competitive edge in protein analysis.
  • Fully Automated Process: The sequencing workflow is fully automated from sample preparation to data acquisition, requiring users only to place samples and reagents in the instrument drawer, significantly simplifying operations and improving laboratory efficiency.
  • Future Development Plans: Quantum-Si aims to expand the production of Proteus instruments in collaboration with manufacturing partners to support product development and transfer to manufacturing, with a commercial launch anticipated by the end of 2026, further driving market demand.
  • Market Potential: By simplifying and accelerating protein analysis workflows, Quantum-Si's technology is expected to expedite proteomic discoveries, meeting the growing research demands and enhancing the company's strategic position in the biotechnology sector.
Newsfilter
9.5
04-16Newsfilter
Quantum-Si to Report Q1 2026 Financial Results on May 7
  • Earnings Report Schedule: Quantum-Si will announce its Q1 2026 financial results on May 7, 2026, reflecting the company's commitment to transparency and investor communication, which is expected to attract more investor interest.
  • Executive Conference Call: CEO Jeff Hawkins and CFO Jeff Keyes will host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business update, aiming to bolster investor confidence in the company's future growth.
  • Webcast Participation: Investors can join the live webcast of the conference call via the Investors section of the Quantum-Si website, enhancing interaction between the company and its investors and facilitating timely information dissemination.
  • Platform Technology Advantage: Quantum-Si's platform simplifies protein analysis through single-molecule detection, improving research efficiency and is expected to drive significant breakthroughs in the proteomics field, thereby strengthening the company's competitive position in the market.
Newsfilter
8.5
04-15Newsfilter
Quantum-Si Showcases New Technology at AACR Conference
  • Customer Poster Presentation: Quantum-Si will present two customer posters at the AACR annual meeting from April 17-22, 2026, focusing on DNA repair inhibitors and high-resolution detection of post-translational modifications, showcasing the application potential of its single-molecule protein sequencing technology.
  • Technological Innovation: The first poster, led by Dr. Nigel O'Neil, introduces a method combining deep mutational scanning with next-generation protein sequencing aimed at developing therapeutics targeting DNA repair enzymes, highlighting the technology's significance in cancer treatment.
  • Application Prospects: The second poster, led by Dr. Gloria Sheynkman, demonstrates the ability to detect multiple post-translational modifications using Quantum-Si's single-molecule protein sequencing technology, indicating the technology's broad application potential in biomarker studies.
  • Market Strategy: CEO Jeff Hawkins stated that the company invested significant effort in 2025 to build a pipeline of studies, aiming to enhance market awareness through customer data presentations and lay the groundwork for the upcoming launch of Proteus™.
Newsfilter
3.5
04-14Newsfilter
Quantum-Si Unveils New Research on Human Cohesin Complexes
  • Research Publication: Quantum-Si announced the publication of a collaborative study with the University of British Columbia and B.C. Cancer Research Institute on bioRxiv, revealing that human cohesins form complexes in yeast cells, which may impact cancer drug development.
  • Technological Value: The study utilized Quantum-Si's single-molecule protein sequencing technology to provide direct, unbiased data demonstrating the assembly of human and yeast cohesin proteins into the same complexes, highlighting the technology's significance in mechanistic biology research.
  • Impact on Cancer Research: The dysfunction of cohesins is linked to genomic instability in tumors, and the findings offer new avenues for targeting cancer cells, potentially driving the development of novel anti-cancer therapies.
  • Strategic Positioning: Quantum-Si's platform aims to enhance research efficiency by simplifying and accelerating protein analysis workflows, thereby strengthening its market position in the proteomics field and facilitating future commercialization efforts.
Wall Street analysts forecast QSI stock price to rise
3 Analyst Rating
Wall Street analysts forecast QSI stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
1.50
Averages
2.67
High
4.00
Current: 0.000
sliders
Low
1.50
Averages
2.67
High
4.00
Canaccord
Kyle Mikson
Hold
downgrade
$1
AI Analysis
2026-03-05
Reason
Canaccord
Kyle Mikson
Price Target
$1
AI Analysis
2026-03-05
downgrade
Hold
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Quantum-Si to $1 from $1.50 and keeps a Hold rating on the shares. The firm said 4Q25 results below our estimates and FactSet consensus. They estimate low-single-digit Platinum instrument sales in the quarter, with gross margin of approximately 27%. Importantly, QSI has largely shifted its focus to the launch of the Proteus platform, framing 2026 as a "transition year."
Canaccord
Hold
downgrade
$2
2025-12-22
Reason
Canaccord
Price Target
$2
2025-12-22
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Quantum-Si to $1.50 from $2 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for QSI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Quantum-Si Inc (QSI.O) is 0.00, compared to its 5-year average forward P/E of -4.15. For a more detailed relative valuation and DCF analysis to assess Quantum-Si Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.15
Current PE
0.00
Overvalued PE
-0.71
Undervalued PE
-7.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.44
Current EV/EBITDA
-0.44
Overvalued EV/EBITDA
2.43
Undervalued EV/EBITDA
-5.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
75.86
Current PS
22.08
Overvalued PS
167.18
Undervalued PS
-15.45

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

best stock under 3 usd to invest in now
Intellectia · 86 candidates
Market Cap: >= 100.00MPrice: <= $3.00Rsi Category: moderateMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SLNH logo
SLNH
Soluna Holdings Inc
180.41M
RXT logo
RXT
Rackspace Technology Inc
437.04M
FFAI logo
FFAI
Faraday Future Intelligent Electric Inc
124.31M
RYDE logo
RYDE
Ryde Group Ltd
215.99M
NNBR logo
NNBR
NN Inc
123.47M
HOVR logo
HOVR
New Horizon Aircraft Ltd
109.54M
stocks to buy from 50 cents to 1 $
Intellectia · 277 candidates
Price: $0.50 - $1.00
Ticker
Name
Market Cap$
top bottom
ALIT logo
ALIT
Alight Inc
485.11M
DVLT logo
DVLT
Datavault AI Inc
400.52M
UP logo
UP
Wheels Up Experience Inc
389.82M
LAB logo
LAB
Standard BioTools Inc
357.84M
BYND logo
BYND
Beyond Meat Inc
331.79M
GETY logo
GETY
Getty Images Holdings Inc
321.38M
what should I buy under 1.00 a share?
Intellectia · 344 candidates
Price: $0.10 - $1.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
ALIT logo
ALIT
Alight Inc
507.72M
UP logo
UP
Wheels Up Experience Inc
406.86M
LAB logo
LAB
Standard BioTools Inc
392.26M
GETY logo
GETY
Getty Images Holdings Inc
360.43M
BYND logo
BYND
Beyond Meat Inc
352.61M
CAN logo
CAN
Canaan Inc
345.29M

Whales Holding QSI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Quantum-Si Inc (QSI) stock price today?

The current price of QSI is 0.9066 USD — it has decreased -7.55

What is Quantum-Si Inc (QSI)'s business?

Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.

What is the price predicton of QSI Stock?

Wall Street analysts forecast QSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QSI is2.67 USD with a low forecast of 1.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Quantum-Si Inc (QSI)'s revenue for the last quarter?

Quantum-Si Inc revenue for the last quarter amounts to 442.00K USD, decreased -47.51

What is Quantum-Si Inc (QSI)'s earnings per share (EPS) for the last quarter?

Quantum-Si Inc. EPS for the last quarter amounts to USD, decreased -100.00

How many employees does Quantum-Si Inc (QSI). have?

Quantum-Si Inc (QSI) has 145 emplpoyees as of May 11 2026.

What is Quantum-Si Inc (QSI) market cap?

Today QSI has the market capitalization of 197.42M USD.